1. Anderson RA, Baird DT 2002 Male contraception. Endocr Rev 23:735-762
2. United Nations 2006 Levels and trends of contraceptive use as assessed in 2002. New York: Department of International Economic and Social Affairs
3. WHO Task Force on Methods for the Regulation of Male Fertility 1990 Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet 336:955-959
4. WHO Task Force on Methods for the Regulation of Male Fertility 1996 Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril 65:821-829
5. Handelsman DJ 2003 Hormonal male contraception--lessons from the East when the Western market fails. Journal of Clinical Endocrinology & Metabolism 88:559-561
6. WHO Task Force on Methods for the Determination of the Fertile Period 1983 A prospective multicentre trial of the ovulation method of natural family planning. III Characteristics of the menstrual cycle and of the fertile phase. Fertil Steril 40:773-778
7. Trussell J, Grummer-Strawn L 1990 Contraceptive failure of the ovulation method of periodic abstinence. Fam Plann Perspect 22:65-75
8. Trussell J 2004 Contraceptive failure in the United States. Contraception 70:89-96
9. Rogow D, Horowitz S 1995 Withdrawal: a review of the literature and an agenda for research. Stud Fam Plann 26:140-153
10. Kost K, Singh S, Vaughan B, Trussell J, Bankole A 2008 Estimates of contraceptive failure from the 2002 National Survey of Family Growth. Contraception 77:10-21
11. Moreau C, Trussell J, Rodriguez G, Bajos N, Bouyer J 2007 Contraceptive failure rates in France: results from a population-based survey. Hum Reprod 22:2422-2427
12. Trussell J, Kost K 1987 Contraceptive failure in the Unites States: A critical review of the literature. Stud Fam Plann 18:237-283
13. Potts M, Diggory P 1983 Textbook of Contraceptive Practice. 2nd ed. Cambridge: Cambridge University Press
14. Steiner MJ, Cates W, Jr., Warner L 1999 The real problem with male condoms is nonuse. Sex Transm Dis 26:459-462
15. Grady WR, Klepinger DH, Nelson-Wally A 1999 Contraceptive characteristics: the perceptions and priorities of men and women. Fam Plann Perspect 31:168-175
16. Rosenberg MJ, Waugh MS, Solomon HM, Lyszkowski AD 1996 The male polyurethane condom: a review of current knowledge. Contraception 53:141-146
17. Gallo MF, Grimes DA, Lopez LM, Schulz KF 2006 Non-latex versus latex male condoms for contraception. Cochrane Database Syst Rev:CD003550
18. Cates W, Jr., Steiner MJ 2002 Dual protection against unintended pregnancy and sexually transmitted infections: what is the best contraceptive approach? Sex Transm Dis 29:168-174
19. Carey RF, Lytle CD, Cyr WH 1999 Implications of laboratory tests of condom integrity. Sex Transm Dis 26:216-220
20. Walsh TL, Frezieres RG, Peacock K, Nelson AL, Clark VA, Bernstein L, Wraxall BG 2003 Use of prostate-specific antigen (PSA) to measure semen exposure resulting from male condom failures: implications for contraceptive efficacy and the prevention of sexually transmitted disease. Contraception 67:139-150
21. United Nations 2000 Levels and trends of contraceptive use as assessed in 1998. New York: Department of International Economic and Social Affairs
22. Liskin L, Benoit E, Blackburn R 1992 Vasectomy: New Opportunities. Baltimore: Population Information Program, Johns Hopkins University, Baltimore
23. Schwingl PJ, Guess HA 2000 Safety and effectiveness of vasectomy. Fertility & Sterility 73:923-936
24. Awsare NS, Krishnan J, Boustead GB, Hanbury DC, McNicholas TA 2005 Complications of vasectomy. Ann R Coll Surg Engl 87:406-410
25. Sokal D, Irsula B, Hays M, Chen-Mok M, Barone MA 2004 Vasectomy by ligation and excision, with or without fascial interposition: a randomized controlled trial. BMC Med 2:6
26. Li S, Goldstein M, Zhu J, Huber D 1991 The no-scalpel vasectomy. J Urol 145:341-344
27. Sokal D, McMullen S, Gates D, Dominik R 1999 A comparative study of the no scalpel and standard incision approaches to vasectomy in 5 countries. The Male Sterilization Investigator Team. J Urol 162:1621-1625
28. Cook LA, Pun A, van Vliet H, Gallo MF, Lopez LM 2007 Scalpel versus no-scalpel incision for vasectomy. Cochrane Database Syst Rev:CD004112
29. Barone MA, Irsula B, Chen-Mok M, Sokal DC 2004 Effectiveness of vasectomy using cautery. BMC Urol 4:10
30. Sokal D, Irsula B, Chen-Mok M, Labrecque M, Barone MA 2004 A comparison of vas occlusion techniques: cautery more effective than ligation and excision with fascial interposition. BMC Urol 4:12
31. Shapiro EI, Silber SJ 1979 Open-ended vasectomy, sperm granuloma, and postvasectomy orchialgia. Fertil Steril 32:546-550
32. Errey BB, Edwards IS 1986 Open-ended vasectomy: an assessment. Fertil Steril 45:843-846
33. Moss WM 1992 A comparison of open-end versus closed-end vasectomies: a report on 6220 cases. Contraception 46:521-525
34. Berthelsen JG 1976 Peroperative irrigation of the vas deferens during vasectomy. Scandanavian Journal of Urology and Nephrology 10:100-102
35. Leungwattanakij S, Lertsuwannaroj A, Ratana-Olarn K 2001 Irrigation of the distal vas deferens during vasectomy: does it accelerate the post-vasectomy sperm-free rate? Int J Androl 24:241-245
36. Mason RG, Dodds L, Swami SK 2002 Sterile water irrigation of the distal vas deferens at vasectomy: does it accelerate clearance of sperm? A prospective randomized trial. Urology 59:424-427
37. Pearce I, Adeyoju A, Bhatt RI, Mokete M, Brown SC 2002 The effect of perioperative distal vasal lavage on subsequent semen analysis after vasectomy: a prospective randomized controlled trial. BJU Int 90:282-285
38. Eisner B, Schuster T, Rodgers P, Ahmed M, Faerber G, Smith G, Ohl D 2004 A randomized clinical trial of the effect of intraoperative saline perfusion on postvasectomy azoospermia. Ann Fam Med 2:221-223
39. Albert PS, Seebode J 1977 Nitrofurazone: vas irrigation as adjunct in vasectomy. Urology 10:450-451
40. Edwards IS 1977 Vasectomy: irrigation with euflavine. Med J Aust 1:847-849
41. Gandrup P, Berthelsen JG, Nielsen OS 1982 Irrigation during vasectomy: a comparison between sterile water and the spermicide euflavine. J Urol 127:60-61
42. Henry Yu HY, Halim A, Evans PR 1976 Chlorhexidine for irrigation of vas: a clinical trial and the study of viability of non-motile sperms in post-vasectomy patients with trypan blue uptake. Br J Urol 48:371-375
43. Cook LA, Van Vliet H, Lopez LM, Pun A, Gallo MF 2007 Vasectomy occlusion techniques for male sterilization. Cochrane Database Syst Rev:CD003991
44. Wood BL, Doncel GF, Reddy PR, Sokal DC 2003 Effect of diltiazem and methylene blue on human sperm motility, viability and cervical mucus penetration: potential use as vas irrigants at the time of vasectomy. Contraception 67:241-245
45. Badrakumar C, Gogoi NK, Sundaram SK 2000 Semen analysis after vasectomy: when and how many? BJU Int 86:479-481
46. Griffin T, Tooher R, Nowakowski K, Lloyd M, Maddern G 2005 How little is enough? The evidence for post-vasectomy testing. J Urol 174:29-36
47. Labrecque M, Barone MA, Pile J, Sokal DC 2006 Re: How little is enough? The evidence for post-vasectomy testing. J Urol 175:791-792; author reply 792
48. Makhlouf AA, Niederberger CS 2006 Ensuring vasectomy success: what is the standard? J Androl 27:637-640
49. Barone MA, Nazerali H, Cortes M, Chen-Mok M, Pollack AE, Sokal D 2003 A prospective study of time and number of ejaculations to azoospermia after vasectomy by ligation and excision. J Urol 170:892-896
50. Labrecque M, Hays M, Chen-Mok M, Barone MA, Sokal D 2006 Frequency and patterns of early recanalization after vasectomy. BMC Urol 6:25
51. Deneux-Tharaux C, Kahn E, Nazerali H, Sokal DC 2004 Pregnancy rates after vasectomy: a survey of US urologists. Contraception 69:401-406
52. Philp T, Guillebaud J, Budd D 1984 Complications of vasectomy: review of 16,000 patients. Br J Urol 56:745-748
53. Rubin GL, Ory HW, Layde PM 1982 The mortality risk of voluntary surgical contraception. Biomed Bull 3:1-5
54. Peng XS, Li FD, Miao ZR, Ye XM, Wong Y, Hu XZ, Zhong ZZ, Zeng FX, Wu XQ, Lan J, et al. 1987 Plasma reproductive hormones in normal and vasectomized Chinese males. Int J Androl 10:471-479
55. Petitti DB 1986 Epidemiologic studies of vasectomy. In: Zatuchni GI, Goldsmith A, Spieler JM, Sciarra JJ eds. Male Contraception: Advances and future prospects. Philadelphia: Harper & Row; 24-33
56. Giovannucci E, Tosteson TD, Speizer FE, Vessey MP, Colditz GA 1992 A long-term study of mortality in men who have undergone vasectomy. N Engl J Med 326:1392-1398
57. Nienhuis H, Goldacre M, Seagroatt V, Gill L, Vessey M 1992 Incidence of disease after vasectomy: a record linkage retrospective cohort study. BMJ 304:743-746
58. Moller H, Knudsen LB, Lynge E 1994 Risk of testicular cancer after vasectomy: cohort study of over 73,000 men. BMJ 309:295-299
59. Strader CH, Weiss NS, Daling JR 1988 Vasectomy and the incidence of testicular cancer. Am J Epidemiol 128:56-63
60. Giovannucci E, Tosteson TD, Speizer FE, Ascherio A, Vessey MP, Colditz GA 1993 A retrospective cohort study of vasectomy and prostate cancer in US men. JAMA 269:878-882
61. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, Willett WC 1993 A prospective cohort study of vasectomy and prostate cancer in US men. JAMA 269:873-877
62. Borgmeier I, Holman CD 2004 Does vasectomy reversal protect against prostate cancer? Ann Epidemiol 14:748-749
63. Bernal-Delgado E, Latour-Perez J, Pradas-Arnal F, Gomez-Lopez LI 1998 The association between vasectomy and prostate cancer: a systematic review of the literature. Fertil Steril 70:191-200
64. Dennis LK, Dawson DV, Resnick MI 2002 Vasectomy and the risk of prostate cancer: a meta-analysis examining vasectomy status, age at vasectomy, and time since vasectomy. Prostate Cancer Prostatic Dis 5:193-203
65. Cox B, Sneyd MJ, Paul C, Delahunt B, Skegg DC 2002 Vasectomy and risk of prostate cancer. JAMA 287:3110-3115
66. Carbone DJ, Jr., Shah A, Thomas AJ, Jr., Agarwal A 1998 Partial obstruction, not antisperm antibodies, causing infertility after vasovasostomy. J Urol 159:827-830
67. Royle MG, Parslow JM, Kingscott MM, Wallace DM, Hendry WF 1981 Reversal of vasectomy: the effects of sperm antibodies on subsequent fertility. Br J Urol 53:654-659
68. Holman CD, Wisniewski ZS, Semmens JB, Rouse IL, Bass AJ 2000 Population-based outcomes after 28,246 in-hospital vasectomies and 1,902 vasovasostomies in Western Australia. BJU Int 86:1043-1049
69. Silber SJ, Grotjan HE 2004 Microscopic vasectomy reversal 30 years later: a summary of 4010 cases by the same surgeon. J Androl 25:845-859
70. Hsieh MH, Meng MV, Turek PJ 2007 Markov modeling of vasectomy reversal and ART for infertility: how do obstructive interval and female partner age influence cost effectiveness? Fertil Steril 88:840-846
71. Kuang W, Shin PR, Oder M, Thomas AJ, Jr. 2005 Robotic-assisted vasovasostomy: a two-layer technique in an animal model. Urology 65:811-814
72. Schiff J, Li PS, Goldstein M 2005 Robotic microsurgical vasovasostomy and vasoepididymostomy in rats. Int J Med Robot 1:122-126
73. Witt MA, Heron S, Lipshultz LI 1994 The post-vasectomy length of the testicular vasal remnant: a predictor of surgical outcome in microscopic vasectomy reversal. J Urol 151:892-894
74. Labrecque M, Hoang DQ, Turcot L 2003 Association between the length of the vas deferens excised during vasectomy and the risk of postvasectomy recanalization. Fertil Steril 79:1003-1007
75. Gerrard ER, Jr., Sandlow JI, Oster RA, Burns JR, Box LC, Kolettis PN 2007 Effect of female partner age on pregnancy rates after vasectomy reversal. Fertil Steril 87:1340-1344
76. Shiraishi K, Takihara H, Naito K 2003 Quantitative analysis of testicular interstitial fibrosis after vasectomy in humans. Aktuelle Urol 34:262-264
77. Raleigh D, O'Donnell L, Southwick GJ, De Kretser DM, McLachlan RI 2004 Stereological analysis of the human testis after vasectomy: impairment of spermatogenic efficiency with increasing obstructive interval. Fertil Steril 81:1595-1603
78. Silber SJ 1979 Epididymal extravasation following vasectomy as a cause for failure of vasectomy reversal. Fertil Steril 31:309-315
79. Andonian S, Jarvi K, Zini A, Hermo L 2002 Ultrastructural features of the vas deferens from patients undergoing vasectomy and vasectomy reversal. J Androl 23:691-701
80. Jarow JP, Budin RE, Dym M, Zirkin BR, Noren S, Marshall FF 1985 Quantitative pathologic changes in the human testis after vasectomy. A controlled study. N Engl J Med 313:1252-1256
81. Shiraishi K, Takihara H, Naito K 2002 Influence of interstitial fibrosis on spermatogenesis after vasectomy and vasovasostomy. Contraception 65:245-249.
82. Pavlovich CP, Schlegel PN 1997 Fertility options after vasectomy: a cost-effectiveness analysis. Fertility & Sterility 67:133-141
83. Heidenreich A, Altmann P, Engelmann UH 2000 Microsurgical vasovasostomy versus microsurgical epididymal sperm aspiration/testicular extraction of sperm combined with intracytoplasmic sperm injection. A cost-benefit analysis. Eur Urol 37:609-614
84. Zhang GY, Wang XH, Chen ZW, Cui YG 1997 Research on male contraception in China. In: Waites GMH, Frick J, Baker GWH eds. Current Advances in Andrology. Bologna: Monduzzi Editore; 233-239
85. Zhao S-C 1990 Vas deferens occlusion by percutaneous injection of polyurethane elastomer plugs: clinical experience and reversibility. Contraception 41:453-459
86. Soebadi DM, Gardjito W, Mensink HJ 1995 Intravasal injection of formed-in-place medical grade silicone rubber for vas occlusion. Int J Androl 18 Suppl 1:45-52
87. Zambon JV, Barone MA, Pollack AE, Mehta M 2000 Efficacy of percutaneous vas occlusion compared with conventional vasectomy. BJU Int 86:699-705; discussion 705-696.
88. Song L, Gu Y, Lu W, Liang X, Chen Z 2006 A phase II randomized controlled trial of a novel male contraception, an intra-vas device. Int J Androl 29:489-495
89. Guha SK, Singh G, Ansari S, Kumar S, Srivastava A, Koul V, Das HC, Malhotra RL, Das SK 1997 Phase II clinical trial of a vas deferens injectable contraceptive for the male. Contraception 56:245-250
90. Guha SK 2007 Biophysical mechanism-mediated time-dependent effect on sperm of human and monkey vas implanted polyelectrolyte contraceptive. Asian J Androl 9:221-227
91. Moore CR, Oslund R 1924 Experiments on the sheep testis - cryptorchidism, vasectomy and scrotal insulation. Am J Physiol 67:595-607
92. Kandeel FR, Swerdloff RS 1988 Role of temperature in regulation of spermatogenesis and the use of heating as a method for contraception. Fertil Steril 49:1-23
93. Thonneau P, Bujan L, Multigner L, Mieusset R 1998 Occupational heat exposure and male fertility: a review. Hum Reprod 13:2122-2125
94. Mieusset R, Bujan L 1994 The potential of mild testicular heating as a safe, effective and reversible contraceptive method for men. Int J Androl 17:186-191
95. Wang C, McDonald V, Leung A, Superlano L, Berman N, Hull L, Swerdloff RS 1997 Effect of increased scrotal temperature on sperm production in normal men. Fertility & Sterility 68:334-339
96. Setchell BP 1998 The Parkes Lecture. Heat and the testis. J Reprod Fertil 114:179-194
97. Baskin MJ 1932 Temporary sterilization by injection of human spermatozoa: a preliminary report. Am J Obstet Gynecol 24:892-897
98. Naz RK, Rajesh C 2004 Passive immunization for immunocontraception: lessons learned from infectious diseases. Front Biosci 9:2457-2465
99. McLaughlin EA, Holland MK, Aitken RJ 2003 Contraceptive vaccines. Expert Opin Biol Ther 3:829-841
100. Ford WCL, Waites GMH 1978 Chlorinated sugars: a biochemical approach to the control of male fertility. Int J Androl Suppl2:541-564
101. van der Spoel AC, Jeyakumar M, Butters TD, Charlton HM, Moore HD, Dwek RA, Platt FM 2002 Reversible infertility in male mice after oral administration of alkylated imino sugars: a nonhormonal approach to male contraception. Proc Natl Acad Sci U S A 99:17173-17178
102. Suganuma R, Walden CM, Butters TD, Platt FM, Dwek RA, Yanagimachi R, van der Spoel AC 2005 Alkylated imino sugars, reversible male infertility-inducing agents, do not affect the genetic integrity of male mouse germ cells during short-term treatment despite induction of sperm deformities. Biol Reprod 72:805-813
103. Walden CM, Butters TD, Dwek RA, Platt FM, van der Spoel AC 2006 Long-term non-hormonal male contraception in mice using N-butyldeoxynojirimycin. Hum Reprod 21:1309-1315
104. Bone W, Walden CM, Fritsch M, Voigtmann U, Leifke E, Gottwald U, Boomkamp S, Platt FM, van der Spoel AC 2007 The sensitivity of murine spermiogenesis to miglustat is a quantitative trait: a pharmacogenetic study. Reprod Biol Endocrinol 5:1
105. Amory JK, Muller CH, Page ST, Leifke E, Pagel ER, Bhandari A, Subramanyam B, Bone W, Radlmaier A, Bremner WJ 2007 Miglustat has no apparent effect on spermatogenesis in normal men. Hum Reprod 22:702-707
106. Matzuk MM, Lamb DJ 2002 Genetic dissection of mammalian fertility pathways. Nat Cell Biol 4 Suppl:s41-49
107. Vickery BH, Grigg MB, Goodpasture JC, Bergstrom KK, Walker KAM 1986 Towards a same-day, orally administered male contraceptive. In: Zatuchni GI, Goldsmith A, Spieler JM, Sciarra JJ eds. Male Contraception Advances and Future Prospects. Philadelphia: Harper & Row; 271-292
108. Giwercman A, Skakkebaek NE 1986 The effect of salicylazosulphapyridine (sulphasalazine) on male fertility. A review. Int J Androl 9:38-52
109. Kjaergaard N, Kjaergaard B, Lauritsen JG 1988 Prazosin, an adrenergic blocking agent inadequate as male contraceptive pill. Contraception 37:621-629
110. Wu D 1989 An overview of the clinical pharmacology and therapeutic potential of goosypol as a male contraceptive agent and in gynaecological disease. Drugs 38:333-341
111. Waites GMH, Wang C, Griffin PD 1998 Gossypol: reasons for its failure to be accepted as a safe, reversible male antifertility agent. Int J Androl 21:8-12
112. Huynh PN, Hikim AP, Wang C, Stefonovic K, Lue YH, Leung A, Atienza V, Baravarian S, Reutrakul V, Swerdloff RS 2000 Long-term effects of triptolide on spermatogenesis, epididymal sperm function, and fertility in male rats. J Androl 21:689-699
113. Breton S, Smith PJ, Lui B, Brown D 1996 Acidification of the male reproductive tract by a proton pumping (H+)-ATPase. Nat Med 2:470-472
114. Ren D, Navarro B, Perez G, Jackson A, Hsu S, Shi Q, Tilly J, Clapham D 2001 A sperm ion channel required for sperm motility and male fertility. Nature 413:603-609
115. Liu J, Xia J, Cho KH, Clapham DE, Ren D 2007 CatSperbeta, a novel transmembrane protein in the CatSper channel complex. J Biol Chem 282:18945-18952
116. Navarro B, Kirichok Y, Clapham DE 2007 KSper, a pH-sensitive K+ current that controls sperm membrane potential. Proc Natl Acad Sci U S A 104:7688-7692
117. Kirichok Y, Navarro B, Clapham DE 2006 Whole-cell patch-clamp measurements of spermatozoa reveal an alkaline-activated Ca2+ channel. Nature 439:737-740
118. Carlson AE, Westenbroek RE, Quill T, Ren D, Clapham DE, Hille B, Garbers DL, Babcock DF 2003 CatSper1 required for evoked Ca2+ entry and control of flagellar function in sperm. Proc Natl Acad Sci U S A 100:14864-14868
119. Quill TA, Ren D, Clapham DE, Garbers DL 2001 A voltage-gated ion channel expressed specifically in spermatozoa. Proc Natl Acad Sci U S A 98:12527-12531
120. Qi H, Moran MM, Navarro B, Chong JA, Krapivinsky G, Krapivinsky L, Kirichok Y, Ramsey IS, Quill TA, Clapham DE 2007 All four CatSper ion channel proteins are required for male fertility and sperm cell hyperactivated motility. Proc Natl Acad Sci U S A 104:1219-1223
121. Esposito G, Jaiswal BS, Xie F, Krajnc-Franken MA, Robben TJ, Strik AM, Kuil C, Philipsen RL, van Duin M, Conti M, Gossen JA 2004 Mice deficient for soluble adenylyl cyclase are infertile because of a severe sperm-motility defect. Proc Natl Acad Sci U S A 101:2993-2998
122. Xie F, Garcia MA, Carlson AE, Schuh SM, Babcock DF, Jaiswal BS, Gossen JA, Esposito G, van Duin M, Conti M 2006 Soluble adenylyl cyclase (sAC) is indispensable for sperm function and fertilization. Dev Biol 296:353-362
123. Sanchez G, Nguyen AN, Timmerberg B, Tash JS, Blanco G 2006 The Na,K-ATPase alpha4 isoform from humans has distinct enzymatic properties and is important for sperm motility. Mol Hum Reprod 12:565-576
124. Mulryan K, Gitterman DP, Lewis CJ, Vial C, Leckie BJ, Cobb AL, Brown JE, Conley EC, Buell G, Pritchard CA, Evans RJ 2000 Reduced vas deferens contraction and male infertility in mice lacking P2X1 receptors. Nature 403:86-89
125. O'Rand MG, Widgren EE, Wang Z, Richardson RT 2007 Eppin: an epididymal protease inhibitor and a target for male contraception. Soc Reprod Fertil Suppl 63:445-453
126. Wolgemuth DJ, Chung SS 2007 Retinoid signaling during spermatogenesis as revealed by genetic and metabolic manipulations of retinoic acid receptor alpha. Soc Reprod Fertil Suppl 63:11-23
127. Chung SS, Wang X, Wolgemuth DJ 2005 Male sterility in mice lacking retinoic acid receptor alpha involves specific abnormalities in spermiogenesis. Differentiation 73:188-198
128. Kamischke A, Nieschlag E 2004 Progress towards hormonal male contraception. Trends Pharmacol Sci 25:49-57
129. Aaltonen P, Amory JK, Anderson RA, Behre HM, Bialy G, Blithe D, Bone W, Bremner WJ, Colvard D, Cooper TG, Elliesen J, Gabelnick HL, Gu YQ, Handelsman DJ, Johansson EA, Kersemaekers W, Liu P, MacKay T, Matlin S, Mbizvo M, McLachlan RI, Meriggiola MC, Mletzko S, Mommers E, Muermans H, Nieschlag E, Odlind V, Page ST, Radlmaier A, Sitruk-Ware R, Swerdloff R, Wang C, Wu F, Zitzmann M 2007 10th Summit Meeting consensus: recommendations for regulatory approval for hormonal male contraception. J Androl 28:362-363
130. Pangkahila W 1991 Reversible azoospermia induced by an androgen-progestagen combination regimen in Indonesian men. Int J Androl 44:248-256
131. World Health Organisation Task Force on Methods for the Regulation of Male Fertility 1993 Comparison of two androgens plus depot-medroxyprogesterone acetate for suppression to azoospermia in Indonesian men. Fertil Steril 60:1062-1068
132. Gu YQ, Wang XH, Xu D, Peng L, Cheng LF, Huang MK, Huang ZJ, Zhang GY 2003 A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese men. J Clin Endocrinol Metab 88:562-568
133. Turner L, Conway AJ, Jimenez M, Liu PY, Forbes E, McLachlan RI, Handelsman DJ 2003 Contraceptive efficacy of a depot progestin and androgen combination in men. J Clin Endocrinol Metab 88:4659-4667
134. Steiner MJ, Hertz-Picciotto I, Schulz KF, Sangi-Haghpeykar H, Earle BB, Trussell J 1998 Measuring true contraceptive efficacy. A randomized approach--condom vs. spermicide vs. no method. Contraception 58:375-378
135. Grimes DA, Lopez LM, Gallo MF, Halpern V, Nanda K, Schulz KF 2007 Steroid hormones for contraception in men. Cochrane Database Syst Rev:CD004316
136. Liu PY, Swerdloff RS, Christenson PD, Handelsman DJ, Wang C, Hormonal Male Contraception Summit Group 2006 Rate, extent and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis. Lancet 367(9520):1412-1420.
137. Heinemann K, Saad F, Wiesemes M, White S, Heinemann L 2005 Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod 20:549-556
138. Heinemann K, Saad F, Wiesemes M, Heinemann LA 2005 Expectations toward a novel male fertility control method and potential user types: results of a multinational survey. J Androl 26:155-162
139. Martin CW, Anderson RA, Cheng L, Ho PC, van der Spuy Z, Smith KB, Glasier AF, Everington D, Baird DT 2000 Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. Hum Reprod 15:637-645
140. Weston GC, Schlipalius ML, Bhuinneanin MN, Vollenhoven BJ 2002 Will Australian men use male hormonal contraception? Med J Aust 176:208-210
141. Glasier AF, Anakwe R, Everington D, Martin CW, van der Spuy Z, Cheng L, Ho PC, Anderson RA 2000 Would women trust their partners to use a male pill? Hum Reprod 15:646-649
142. Meriggiola MC, Cerpolini S, Bremner WJ, Mbizvo MT, Vogelsong KM, Martorana G, Pelusi G 2006 Acceptability of an injectable male contraceptive regimen of norethisterone enanthate and testosterone undecanoate for men. Hum Reprod 21:2033-2040
143. Amory JK, Page ST, Anawalt BD, Matsumoto AM, Bremner WJ 2007 Acceptability of a combination testosterone gel and depomedroxyprogesterone acetate male contraceptive regimen. Contraception 75:218-223
144. Heckel NJ 1939 Production of oligospermia in a man by the use of testosterone propionate. Proc Soc Exp Biol Med 40:658-659
145. McCullagh EP, McGurl FJ 1940 The effects of testosterone propionate on epiphyseal closure, sodium and chloride balance and on sperm counts. Endocrinology 26:377-384
146. Heller CG, Nelson WO, Hill IB, Henderson E, Maddock WO, Jungck EC, Paulsen CA, Mortimore GE 1950 Improvement in spermatogenesis following depression of the human testis with testosterone. Fertil Steril 1:415-422
147. Heckel NJ, Rosso WA, Kestel L 1951 Spermatogenic rebound phenomenon after administration of testosterone propionate. J Clin Endocrinol Metab 11:235-245
148. Reddy PRK, Rao JM 1972 Reversible antifertility action of testosterone propionate in human males. Contraception 5:295-301
149. Mauss J, Borsch G, Richter E, Bormacher K 1974 Investigations on the use of testosterone oenanthate as a male contraceptive agent. A preliminary report. Contraception 10:281-289
150. Patanelli DJ ed. 1977 Hormonal control of fertility. Washington: US Department of Health Education and Welfare,
151. Matsumoto AM 1990 Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone and sperm production. J Clin Endocrinol Metab 70:282-287
152. Cunningham GR, Silverman VE, Thornby J, Kohler PO 1979 The potential for an androgen male contraceptive. J Clin Endocrinol Metab 49:520-526
153. Steinberger E, Smith KD, Rodriguez-Rigau LJ 1978 Suppression and recovery of sperm production in men treated with testosterone enanthate for one year. A study of a possible reversible male contraceptive. Int J Androl Suppl 2:748-760
154. Swerdloff RS, Palacios A, McClure RD, Campfield LA, Brosman SA 1978 Male contraception: clinical assessment of chronic administration of testosterone enanthate. Int J Androl Suppl 2:731-747
155. Paulsen CA 1978 Male contraceptive development: re-examination of testosterone enanthate as an effective single entity agent. In: Patanelli DJ ed. Hormonal Control of Male Fertility. Washington: Department of Health Education and Welfare; 17-40
156. Handelsman DJ, Farley TMM, Peregoudov A, Waites GMH, WHO Task Force On Methods For The Regulation Of Male Fertility 1995 Factors in nonuniform induction of azoospermia by testosterone enanthate in normal men. Fertil Steril 63:125-133
157. McLachlan RI, O'Donnell L, Meachem SJ, Stanton PG, de K, Pratis K, Robertson DM 2002 Hormonal regulation of spermatogenesis in primates and man: insights for development of the male hormonal contraceptive. J Androl 23:149-162
158. Nieschlag E, Zitzmann M, Kamischke A 2003 Use of progestins in male contraception. Steroids 68:965-972
159. McLachlan RI, Robertson DM, Pruysers E, Ugoni A, Matsumoto AM, Anawalt BD, Bremner WJ, Meriggiola C 2004 Relationship between serum gonadotropins and spermatogenic suppression in men undergoing steroidal contraceptive treatment. J Clin Endocrinol Metab 89:142-149
160. Matthiesson KL, McLachlan RI, O'Donnell L, Frydenberg M, Robertson DM, Stanton PG, Meachem SJ 2006 The relative roles of follicle-stimulating hormone and luteinizing hormone in maintaining spermatogonial maturation and spermiation in normal men. J Clin Endocrinol Metab 91:3962-3969
161. Weinbauer GF, Schlatt S, Walter V, Nieschlag E 2001 Testosterone-induced inhibition of spermatogenesis is more closely related to suppression of FSH than to testicular androgen levels in the cynomolgus monkey model (Macaca fascicularis). J Endocrinol 168:25-38
162. Narula A, Gu YQ, O'Donnell L, Stanton PG, Robertson DM, McLachlan RI, Bremner WJ 2002 Variability in sperm suppression during testosterone administration to adult monkeys is related to follicle stimulating hormone suppression and not to intratesticular androgens. J Clin Endocrinol Metab 87:3399-3406
163. Santner S, Albertson B, Zhang GY, Zhang GH, Santulli M, Wang C, Demers LM, Shackleton C, Santen RJ 1998 Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects. J Clin Endocrinol Metab 83:2104-2109
164. Jin B, Turner L, Zhou Z, Zhou EL, Handelsman DJ 1999 Ethnicity and migration as determinants of human prostate size. J Clin Endocrinol Metab 84:3613-3619
165. Yu B, Handelsman DJ 2001 Pharmacogenetic polymorphisms of the AR and metabolism and susceptibility to hormone- induced azoospermia. J Clin Endocrinol Metab 86:4406-4411.
166. Eckardstein SV, Schmidt A, Kamischke A, Simoni M, Gromoll J, Nieschlag E 2002 CAG repeat length in the androgen receptor gene and gonadotrophin suppression influence the effectiveness of hormonal male contraception. Clin Endocrinol (Oxf) 57:647-655
167. Johnson L, Barnard JJ, Rodriguez L, Smith EC, Swerdloff RS, Wang XH, Wang C 1998 Ethnic differences in testicular structure and spermatogenic potential may predispose testes of Asian men to a heightened sensitivity to steroidal contraceptives. J Androl 19:348-357
168. Veldhuis JD, Bae A, Swerdloff RS, Iranmanesh A, Wang C 2005 Experimentally induced androgen depletion accentuates ethnicity-related contrasts in luteinizing hormone secretion in asian and caucasian men. J Clin Endocrinol Metab 90:1632-1638
169. Coviello AD, Bremner WJ, Matsumoto AM, Herbst KL, Amory JK, Anawalt BD, Yan X, Brown TR, Wright WW, Zirkin BR, Jarow JP 2004 Intratesticular testosterone concentrations comparable with serum levels are not sufficient to maintain normal sperm production in men receiving a hormonal contraceptive regimen. J Androl 25:931-938
170. Matthiesson KL, Amory JK, Berger R, Ugoni A, McLachlan RI, Bremner WJ 2004 Novel male hormonal contraceptive combinations: the hormonal and spermatogenic effects of testosterone and levonorgestrel combined with a 5alpha-reductase inhibitor or gonadotropin-releasing hormone antagonist. J Clin Endocrinol Metab
171. Page ST, Kalhorn TF, Bremner WJ, Anawalt BD, Matsumoto AM, Amory JK 2007 Intratesticular androgens and spermatogenesis during severe gonadotropin suppression induced by male hormonal contraceptive treatment. J Androl 28:734-741
172. Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA 1996 Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot. J Clin Endocrinol Metab 81:4113-4121
173. Amory JK, Coviello AD, Page ST, Anawalt BD, Matsumoto AM, Bremner WJ 2007 Serum 17-hydroxyprogesterone strongly correlates with intratesticular testosterone in gonadotropin-suppressed normal men receiving various dosages of human chorionic gonadotropin. Fertil Steril
174. Amory JK, Page ST, Anawalt BD, Coviello AD, Matsumoto AM, Bremner WJ 2007 Elevated end-of-treatment serum INSL3 is associated with failure to completely suppress spermatogenesis in men receiving male hormonal contraception. J Androl 28:548-554
175. Ly LP, Liu PY, Handelsman DJ 2005 Rates of suppression and recovery of human sperm output in testosterone-based hormonal contraceptive regimens. Hum Reprod 20:1733-1740
176. Wu FCW, Farley TMM, Peregoudov A, Waites GMH, WHO Task Force on Methods for the Regulation of Male Fertility 1996 Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. Fertil Steril 65:626-636
177. Mackey MA, Conway AJ, Handelsman DJ 1995 Tolerability of intramuscular injections of testosterone ester in an oil vehicle. Hum Reprod 10:862-865
178. McLachlan RI, O'Donnell L, Stanton PG, Balourdos G, Frydenberg M, de Kretser DM, Robertson DM 2002 Effects of testosterone plus medroxyprogesterone acetate on semen quality, reproductive hormones, and germ cell populations in normal young men. J Clin Endocrinol Metab 87:546-556.
179. Meriggiola MC, Costantino A, Bremner WJ, Morselli-Labate AM 2002 Higher testosterone dose impairs sperm suppression induced by a combined androgen-progestin regimen. J Androl 23:684-690
180. Behre HM, Nieschlag E 1998 Comparative pharmacokinetics of testosterone esters. In: Nieschlag E, Behre HM eds. Testosterone: Action Deficiency Substitution. 2nd ed. Berlin: Springer; 329-348
181. Handelsman DJ, Conway AJ, Boylan LM 1990 Pharmacokinetics and pharmacodynamics of testosterone pellets in man. J Clin Endocrinol Metab 71:216-222
182. Amory JK, Anawalt BD, Blaskovich PD, Gilchriest J, Nuwayser ES, Matsumoto AM 2002 Testosterone release from a subcutaneous, biodegradable microcapsule formulation (Viatrel) in hypogonadal men. J Androl 23:84-91
183. Behre HM, Baus S, Kliesch S, Keck C, Simoni M, Nieschlag E 1995 Potential of testosterone buciclate for male contraception: endocrine differences between responders and nonresponders. J Clin Endocrinol Metab 80:2394-2403
184. Handelsman DJ, Conway AJ, Boylan LM 1992 Suppression of human spermatogenesis by testosterone implants in man. J Clin Endocrinol Metab 75:1326-1332
185. McCullagh EP, Rossmiller HR 1941 Methyl testosterone. I androgenic effects and production of gynecomastia and oligospermia. J Clin Endocrinol Metab 1
186. Jones TM, Fang VS, Landau RL, Rosenfield RL 1977 The effects of fluoxymesterone administration on testicular function. J Clin Endocrinol Metab 44:121-129
187. Holma PK 1977 Effects of an anabolic steroid (metandienone) on spermatogenesis. Contraception 15:151-162
188. Skoglund RD, Paulsen CA 1973 Danazol-testosterone combination: a potentially effective means for reversible male contraception. a preliminary report. Contraception 7:357-365
189. Sherins RJ, Gandy HM, Thorslund TW, Paulsen CA 1971 Pituitary and testicular function studies. I. Experience with a new gonadal inhibitor, 17a-pregn-4-en-20-yno-(2,3-d) isoxazol-17-ol (Danazol). J Clin Endocrinol Metab 32:522-531
190. Ishak KG, Zimmerman HJ 1987 Hepatotoxic effects of the anabolic-androgenic steroids. Semin Liver Dis 7:230-236
191. Knuth UA, Maniera H, Nieschlag E 1989 Anabolic steroids and semen parameters in bodybuilders. Fertil Steril 52:1041-1047
192. Knuth UA, Behre H, Belkien L, Bents H, Nieschlag E 1985 Clinical trial of 19-nortestosterone hexoxyphenylpropionate (Anadur) for male fertility regulation. Fertil Steril 44:814-821
193. Schurmeyer T, Knuth UA, Belkein L, Nieschlag E 1984 Reversible azoospermia induced by the anabolic steroid 19-nortestosterone. Lancet 1:417-420
194. Schellen TNCM, Beek JMJHA 1972 The influence of high doses of mesterolone on the spermiogram. Fertil Steril 23:712-714
195. Behre HM, Kliesch S, Lemcke B, von Eckardstein S, Nieschlag E 2001 Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. Hum Reprod 16:2570-2577
196. Swerdloff RS, Bagatell CJ, Wang C, Anawalt BD, Berman N, Steiner B, Bremner WJ 1998 Suppression of spermatogenesis in man induced by Nal-Glu gonadotropin releasing hormone antagonist and testosterone enanthate (TE) in maintained by TE alone. J Clin Endocrinol Metab 83:3527-3533
197. Sundaram K, Kumar N 2000 7alpha-methyl-19-nortestosterone (MENT): the optimal androgen for male contraception and replacement therapy. Int J Androl 23 Suppl 2:13-15
198. Cummings DE, Kumar N, Bardin CW, Sundaram K, Bremner WJ 1998 Prostate-sparing effects in primates of the potent androgen 7alpha-methyl-19-nortestosterone: a potential alternative to testosterone for androgen replacement and male contraception. Journal of Clinical Endocrinology & Metabolism 83:4212-4219
199. Anderson RA, Wallace AM, Sattar N, Kumar N, Sundaram K 2003 Evidence for tissue selectivity of the synthetic androgen 7 alpha-methyl-19-nortestosterone in hypogonadal men. J Clin Endocrinol Metab 88:2784-2793
200. Avery MA, Tanabe M, Crowe DF, Detre G, Peters RH, Chong WKM 1990 Synthesis and testing of 17ab-hydroxy-7a methyl-D-homoestra-4,16-dien-3-one: a highly potent orally active androgen. Steroids 55:59-64
201. Grootenhuis AJ, de Gooyer ME, Louw J, Bursi R, Leysen D 2004 Synthesis and pharmacological profiling of new orally active steroidal androgens. In: Nieschlag E, Behre HM eds. Testosterone: Action, Deficiency and Substitution. 3rd ed. Berlin: Springer-Verlag; 665-684
202. Prasad MRN, Singh SP, Rajalakshmi M 1970 Fertility control in male rats by continuous release of microquantities of cyproterone acetate from subcutaneous silastic capsules. Contraception 2:165-178
203. Wang C, Yeung KK 1980 Use of low-dosage oral cyproterone acetate as a male contraceptive. Contraception 21:245-272
204. Chandolia RK, Weinbauer GF, Simoni M, Behre HM, Nieschlag E 1991 Comparative effects of chronic administration of the non-steroidal antiandrogens flutamide and casodex on the reproductive system of the male rat. Acta Endocr 125:547-555
205. Dhar JD, Sety BS 1990 Effect of a nonsteroidal antiandrogen, anadron, on the reproductive system and fertility in male rats. Contraception 42:121-138
206. McLachlan RI, McDonald J, Rushford D, Robertson DM, Garrett C, Baker HW 2000 Efficacy and acceptability of testosterone implants, alone or in combination with a 5alpha-reductase inhibitor, for male hormonal contraception. Contraception 62:73-78
207. Kinniburgh D, Anderson RA, Baird DT 2001 Suppression of spermatogenesis with desogestrel and testosterone pellets is not enhanced by addition of finasteride. J Androl 22:88-95
208. Killian J, Pratis K, Clifton RJ, Stanton PG, Robertson DM, O'Donnell L 2003 5alpha-reductase isoenzymes 1 and 2 in the rat testis during postnatal development. Biol Reprod 68:1711-1718
209. Amory JK, Kalhorn TF, Page ST 2007 Pharmacokinetics and Pharmacodynamics of Oral Testosterone Enanthate Plus Dutasteride for Four Weeks in Normal Men: Implications for Male Hormonal Contraception. J Androl
210. Wu FC, von Eckardstein A 2003 Androgens and coronary artery disease. Endocr Rev 24:183-217
211. Liu PY, Death AK, Handelsman DJ 2003 Androgens and cardiovascular disease. Endocr Rev 24:313-340
212. Atkinson LE, Chang YL, Snyder PJ 1998 Long-term experience with testosterone replacement through scrotal skin. In: Nieschlag E, Behre HM eds. Testosterone: Action Deficiency Substitution. 2nd ed. Berlin: Springer; 364-388
213. Handelsman DJ 1998 The safety of androgens: prostate and cardiovascular disease. In: Wang C ed. Male Reproductive Function. Boston: Kluwer Academic Publishers; 173-190
214. Wu JP, Gu FL 1987 The prostate 41-65 years post castration. Chin Med J (Engl) 100:271-272
215. Imperato-McGinley J, Gautier T, Zirinsky K, Hom T, Palomo O, Stein E, Vaughan ED, Markisz JA, deArellano ER, Kazam E 1992 Prostate visualization studies in males homozygous and heterozygous for 5-a reductase deficiency. J Clin Endocrinol Metab 75:1022-1026
216. Quigley CA, DeBellis A, Marschke KB, El-Awady MK, Wilson EM, French FF 1995 Androgen receptor defects: historical, clinical and molecular perspectives. Endocr Rev 16:271-321
217. Shaneyfelt T, Husein R, Bubley G, Mantzoros CS 2000 Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 18:847-853
218. Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E 2003 Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. J Clin Endocrinol Metab 88:2049-2054
219. Nelson KA, Witte JS 2002 Androgen receptor CAG repeats and prostate cancer. Am J Epidemiol 155:883-890
220. Behre HM, Bohmeyer J, Nieschlag E 1994 Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 40:341-349
221. Meikle AW, Arver S, Dobs AS, Adolfsson J, Sanders SW, Middleton RG, Stephenson RA, Hoover DR, Rajaram L, Mazer NA 1997 Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system. Urology 49:191-196
222. Jin B, Conway AJ, Handelsman DJ 2001 Effects of androgen deficiency and replacement on prostate zonal volumes. Clin Endocrinol (Oxf) 54:437-445.
223. Jin B, Turner L, Walters WAW, Handelsman DJ 1996 Androgen or estrogen effects on the human prostate. J Clin Endocrinol Metab 81:4290-4295
224. Archer J 1991 The influence of testosterone on human aggression. Br J Psychiatry 82:1-28
225. Anderson RA, Bancroft J, Wu FCW 1992 The effects of exogenous testosterone on sexuality and mood of normal men. J Clin Endocrinol Metab 75:1503-1507
226. Christiansen K 1998 Behavioural correlates of testosterone. In: Nieschlag E, Behre HM eds. Testosterone: Action Deficiency Substitution. 2nd ed. Berlin: Springer; 107-142
227. O'Connor DB, Archer J, Wu FC 2004 Effects of testosterone on mood, aggression, and sexual behavior in young men: a double-blind, placebo-controlled, cross-over study. J Clin Endocrinol Metab 89:2837-2845
228. Pope HG, Jr., Kouri EM, Hudson JI 2000 Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch Gen Psychiatry 57:133-140; discussion 155-136
229. Bahrke MS, Yesalis CE, Wright JE 1990 Psychological and behavioural effects of endogenous testosterone levels and anabolic-androgenic steroids among male. A review. Sports Med 10:303-337
230. Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM 1996 Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab 81:757-762
231. Meriggiola MC, Bremner WJ, Paulsen CA, Valdiserri A, Incorvaia L, Motta R, Pavani A, Capelli M, Flamigni C 1996 A combined regimen of cyproterone acetate and testosterone enanthate as a potentially highly effective male contraceptive. J Clin Endocrinol Metab 81:3018-3023
232. Bouchard P, Garcia E 1987 Influence of testosterone substitution on sperm suppression by LHRH agonists. Hormone Res 28:175-180
233. Behre HM, Nashan D, Hubert W, Nieschlag E 1992 Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception. J Clin Endocrinol Metab 74:84-90
234. Garcia MA, Meizel S 1999 Progesterone-mediated calcium influx and acrosome reaction of human spermatozoa: pharmacological investigation of T-type calcium channels. Biol Reprod 60:102-109
235. Losel RM, Falkenstein E, Feuring M, Schultz A, Tillmann HC, Rossol-Haseroth K, Wehling M 2003 Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 83:965-1016
236. Luetjens CM, Didolkar A, Kliesch S, Paulus W, Jeibmann A, Bocker W, Nieschlag E, Simoni M 2006 Tissue expression of the nuclear progesterone receptor in male non-human primates and men. J Endocrinol 189:529-539
237. Heller CG, Moore DJ, Paulsen CA, Nelson WO, Laidlaw WM 1959 Effects of progesterone and synthetic progestins on the reproductive physiology of normal men. Fed Proc 18:1057-1064
238. Frick J, Danner C, Joos H, Kunit G, Luukkainen T 1981 Spermatogenesis in men treated with subcutaneous application of levonorgestrel and estrone rods. J Androl 2:331-338
239. Junaidi A, Luetjens CM, Wistuba J, Kamischke A, Yeung CH, Simoni M, Nieschlag E 2005 Norethisterone enanthate has neither a direct effect on the testis nor on the epididymis: a study in adult male cynomolgus monkeys (Macaca fascicularis). Eur J Endocrinol 152:655-661
240. Schearer SB, Alvarez-Sanchez F, Anselmo J, Brenner P, Coutinho E, Latham-Faundes A, Frick J, Heinild B, Johansson EDB 1978 Hormonal contraception for men. Int J Androl (suppl 2):680-712
241. Wu FCW, Aitken RJ 1989 Suppression of sperm function by depot medroxyprogesterone acetate and testosterone enanthate in steroid male contraception. Fertil Steril 51:691-698
242. Foegh M 1983 Evaluation of steroids as contraceptives in men. Acta Endocr suppl 260:1-48
243. Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM 1999 A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl 20:407-414
244. Lobel B, Olivo JF, Guille F, D Le Lanou 1989 Contraception in men: efficacy and immediate toxicity, a study of 18 cases. Acta Urol Belg 57:117-124
245. Guerin JF, Rollet J 1988 Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens. Int J Androl 11:187-199
246. Meriggiola MC, Bremner WJ, Constantino A, Di Cintio G, Flamigni C 1998 Low dose of cyproterone acetate and testosterone enanthate for contraception. Hum Reprod 13:1225-1229
247. Meriggiola MC, Pavani A, Bremner WJ, Capelli M, Constantino A, Flamigni C 1997 An oral regimen of cyproterone acetate and testosterone undecanoate for spermatogenic suppression in men. Fertility & Sterility 68:844-850
248. Gonzalo IT, Swerdloff RS, Nelson AL, Clevenger B, Garcia R, Berman N, Wang C 2002 Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. J Clin Endocrinol Metab 87:3562-3572.
249. Gui YL, He CH, Amory JK, Bremner WJ, Zheng EX, Yang J, Yang PJ, Gao ES 2004 Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in chinese men. J Androl 25:720-727
250. Wang C, Wang XH, Nelson AL, Lee KK, Cui YG, Tong JS, Berman N, Lumbreras L, Leung A, Hull L, Desai S, Swerdloff RS 2006 Levonorgestrel implants enhanced the suppression of spermatogenesis by testosterone implants: comparison between Chinese and non-Chinese men. J Clin Endocrinol Metab 91:460-470
251. Anderson RA, Kinniburgh D, Baird DT 2002 Suppression of spermatogenesis by etonogestrel implants with depot testosterone: potential for long-acting male contraception. J Clin Endocrinol Metab 87:3640-3649.
252. Brady BM, Amory JK, Perheentupa A, Zitzmann M, Hay CJ, Apter D, Anderson RA, Bremner WJ, Pollanen P, Nieschlag E, Wu FC, Kersemaekers WM 2006 A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive. Hum Reprod 21:285-294
253. Gu YQ, Tong JS, Ma DZ, Wang XH, Yuan D, Tang WH, Bremner WJ 2004 Male hormonal contraception: effects of injections of testosterone undecanoate and depot medroxyprogesterone acetate at eight-week intervals in chinese men. J Clin Endocrinol Metab 89:2254-2262
254. Page ST, Amory JK, Anawalt BD, Irwig MS, Brockenbrough AT, Matsumoto AM, Bremner WJ 2006 Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. J Clin Endocrinol Metab 91:4374-4380
255. Kamischke A, Heuermann T, Kruger K, von Eckardstein S, Schellschmidt I, Rubig A, Nieschlag E 2002 An effective hormonal male contraceptive using testosterone undecanoate with oral or injectable norethisterone preparations. J Clin Endocrinol Metab 87:530-539
256. Meriggiola MC, Costantino A, Saad F, D'Emidio L, Morselli Labate AM, Bertaccini A, Bremner WJ, Rudolph I, Ernst M, Kirsch B, Martorana G, Pelusi G 2005 Norethisterone enanthate plus testosterone undecanoate for male contraception: effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostate. J Clin Endocrinol Metab 90:2005-2014
257. Ewing LL, Cochran RC, Adams RJ, Darney KJ, Berry SJ, Bordy MJ, Desjardins C 1983 Testis function in rhesus monkeys treated with a contraceptive steroid formulation. Contraception 27:347-362
258. Lobl TJ, Kirton KT, Forbes AD, Ewing LL, Kemp PL, Desjardins C 1983 Contraceptive efficacy of testosterone-estradiol implants in male rhesus monkeys. Contraception 27:383-389
259. Handelsman DJ, Wishart S, Mackey MA, Conway AJ 1998 Efficacy and safety of low dose estradiol supplementation to augment depot testosterone-induced suppression of human spermatogenesis. Annual Scientific Meeting of the Endocrine Society of Australia, Perth, 1998
260. Lunn SF, Dixson AF, Sandow J, Fraser HM 1990 Pituitary-testicular function is suppressed by an LHRH antagonist but not by an LHRH agonist in the marmoset monkey. J Endocrinol 125:233-239
261. Marshall GF, Akhtar FB, Weinbauer GF, Nieschlag E 1986 Gonadotrophin-releasing hormone (GnRH) overcomes GnRH antagonist-induced suppression of LH secretion in primates. J Endocrinol 110:145-150
262. Herbst KL, Coviello AD, Page S, Amory JK, Anawalt BD, Bremner WJ 2004 A single dose of the potent gonadotropin-releasing hormone antagonist acyline suppresses gonadotropins and testosterone for 2 weeks in healthy young men. J Clin Endocrinol Metab 89:5959-5965
263. Weinbauer GF, Surmann FJ, Nieschlag E 1987 Suppression of spermatogenesis in a non-human primate (Macaca fascicularis) by concomitant gonadotrophin-releasing hormone antagonist and testosterone treatment. Acta Endocr 114:138-146
264. Weinbauer GF, Khurshid S, Findscheidt U, Nieschlag E 1989 Sustained inhibition of sperm production and inhibin secretion by a gonadotrophin-releasing hormone antagonist and delayed testosterone substitution in non-human primates (Macaca fascicularis). Acta Endocr 123:303-310
265. Bremner WJ, Bagatell CJ, Steiner RA 1991 Gonadotropin-releasing hormone antagonist plus testosterone: a potential male contraceptive. J Clin Endocrinol Metab 73:465-469
266. Tom L, Bhasin S, Salameh W, Steiner B, Peterson M, Sokol R, Rivier J, Vale WW, Swerdloff RS 1992 Induction of azoospermia in normal men with combined Nal-Glu GnRH antagonist and testosterone enanthate. J Clin Endocrinol Metab 75:476-483
267. Pavlou SN, Brewer K, Farley MG, Lindner J, Bastias MC, Rogers BJ, Swift LL, Rivier JE, Vale WW, Conn PM, Herbert CM 1991 Combined administration of a gonadotropin-releasing hormone antagonist and testosterone in men induces reversible azoospermia without loss of libido. J Clin Endocrinol Metab 73:1360-1369
268. Bagatell CJ, Matsumoto AM, Christensen RB, Rivier JE, Bremner WJ 1993 Comparison of a gonadotropin-releasing hormone antagonist plus testosterone (T) versus T alone as a potential male contraceptive. J Clin Endocrinol Metab 77:427-432
269. Simms MS, Scholfield DP, Jacobs E, Michaeli D, Broome P, Humphreys JE, Bishop MC 2000 Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer. Br J Cancer 83:443-446
270. Talwar GP 1997 Fertility regulating and immunotherapeutic vaccines reaching human trials stage. Hum Reprod Update 3:301-310
271. Naz RK 2005 Contraceptive vaccines. Drugs 65:593-603
272. Naz RK, Gupta SK, Gupta JC, Vyas HK, Talwar AG 2005 Recent advances in contraceptive vaccine development: a mini-review. Hum Reprod 20:3271-3283
273. Delves PJ, Roitt IM 2005 Vaccines for the control of reproduction--status in mammals, and aspects of comparative interest. Dev Biol (Basel) 121:265-273
274. Burger HG 1992 Inhibin. Reproductive Medicine Reviews 1:1-20
275. Wiebe JP, Wood PH 1987 Selective suppression of follicle-stimulating hormone by 3-alpha-hydroxy-4-pregnen-20-one, a steroid found in Sertoli cells. Endocrinology 120:2259-2264
276. Moudgal NR, Jeyakumar M, Krishnamurthy HN, Sridhar S, Krishnamurthy H 1997 Development of male contraceptive vaccine - a perspective. Hum Reprod Update 3:335-346
277. Leng N, Grasso P, Reichert LE 1996 D-amino acid substitution of residues 32 to 46 of the glycoprotein hormone common alpha-subunit: development of a synthetic glycoprotein hormone antagonist. Pept Res 9:188-194
278. Singh J, O'Neill C, Handelsman DJ 1995 Induction of spermatogenesis by androgens in gonadotropin-deficient (hpg) mice. Endocrinology 136:5311-5321
279. Kumar TR, Wang Y, Lu N, Matzuk MM 1997 FSH is required for ovarian follicle maturation but not for male fertility. Nat Genet 15:201-204
280. Dierich A, Sairam MR, Monaco L, Fimia GM, Gansmuller A, LeMeur M, Sassone-Corsi P 1998 Impairing follicle-stimulating hormone (FSH) signalling in-vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance. Proceedings of the National Academy of Sciences USA 95:13612-13617
281. Tapanainen JS, Aittomaki K, Min J, Vasivou T, Huhtaniemi IT 1997 Men homozygous for an inactivating mutation of the follicle-stimulating hormone (FSH) receptor present variable suppression of spermatogenesis and fertility. Nat Genet 15:205-206
282. Nieschlag E 1986 Reasons for abandoning immunization against FSH as an approach to male fertility regulation. In: Zatuchni GI, Goldsmith A, Spieler JM, Sciarra JJ eds. Male Contraception: Advances and Future Prospects. Philadelphia: Harper & Row; 395-400